The cost of targeted therapy for breast cancer is generally determined by the medication used. The main targeted therapy for breast cancer is trastuzumab, which is currently more than 5,000 units and is covered by national health insurance. The amount of trastuzumab needed is determined by the patient’s body weight, and is usually administered every 3 weeks in combination with chemotherapy. Other targeted drugs, including anti-tumor angiogenesis targeted drugs, as well as nidanib targeted therapy drugs, but these drugs are not yet available in China, mainly trastuzumab has entered the Chinese health insurance, has been listed in China.